GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (NAS:KMDA) » Definitions » Cash And Cash Equivalents

Kamada (Kamada) Cash And Cash Equivalents : $48.2 Mil (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Kamada Cash And Cash Equivalents?

Kamada's quarterly cash and cash equivalents increased from Sep. 2023 ($52.60 Mil) to Dec. 2023 ($55.64 Mil) but then stayed the same from Dec. 2023 ($55.64 Mil) to Mar. 2024 ($48.19 Mil).

Kamada's annual cash and cash equivalents increased from Dec. 2021 ($18.59 Mil) to Dec. 2022 ($34.26 Mil) and increased from Dec. 2022 ($34.26 Mil) to Dec. 2023 ($55.64 Mil).


Kamada Cash And Cash Equivalents Historical Data

The historical data trend for Kamada's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Cash And Cash Equivalents Chart

Kamada Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.66 70.20 18.59 34.26 55.64

Kamada Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.12 21.79 52.60 55.64 48.19

Kamada Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Kamada  (NAS:KMDA) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Kamada Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Kamada's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Kamada (Kamada) Business Description

Traded in Other Exchanges
Address
2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Kamada (Kamada) Headlines

From GuruFocus

Kamada to Present at the Credit Suisse 31st Annual Healthcare Conference

By Value_Insider Value_Insider 10-26-2022